Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$241.25
+0.8%		$249.82
$197.81
▼
$495.55
$32.24B0.311.45 million shs247,241 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$68.39
+4.0%		$83.45
$29.81
▼
$95.49
$9.62B1.282.29 million shs1.32 million shs
Biogen Inc. stock logo
BIIB
Biogen
$217.32
+0.6%		$210.27
$135.39
▼
$225.80
$32.09B0.171.19 million shs170,641 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$197.53
+0.8%		$199.37
$42.18
▼
$224.31
$42.41B1.42.91 million shs776,628 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.46%-7.22%+6.57%-13.93%-48.11%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-6.91%-20.38%-25.83%-19.59%+123.62%
Biogen Inc. stock logo
BIIB
Biogen
-0.07%+2.51%+3.28%+9.88%+50.34%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-4.36%-5.66%-7.58%+20.20%+338.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$241.25
+0.8%		$249.82
$197.81
▼
$495.55
$32.24B0.311.45 million shs247,241 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$68.39
+4.0%		$83.45
$29.81
▼
$95.49
$9.62B1.282.29 million shs1.32 million shs
Biogen Inc. stock logo
BIIB
Biogen
$217.32
+0.6%		$210.27
$135.39
▼
$225.80
$32.09B0.171.19 million shs170,641 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$197.53
+0.8%		$199.37
$42.18
▼
$224.31
$42.41B1.42.91 million shs776,628 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.46%-7.22%+6.57%-13.93%-48.11%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-6.91%-20.38%-25.83%-19.59%+123.62%
Biogen Inc. stock logo
BIIB
Biogen
-0.07%+2.51%+3.28%+9.88%+50.34%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-4.36%-5.66%-7.58%+20.20%+338.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.87
Moderate Buy$367.2050.70% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.64
Moderate Buy$99.1546.43% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$230.146.00% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$226.1712.79% Upside

Current Analyst Ratings Breakdown

Latest ARWR, RVMD, ALNY, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$242.00
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetReduce$165.00 ➝ $175.00
9/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Overweight$255.00
9/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$215.00 ➝ $230.00
9/8/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$230.00 ➝ $260.00
9/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$108.00
9/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$225.00 ➝ $245.00
9/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
9/1/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B8.78$2.86 per share85.21$5.97 per share40.81
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M11.50$0.11 per share591.87$3.64 per share18.60
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.24$22.73 per share9.55$124.45 per share1.74
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,711.69N/AN/A$8.44 per share23.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3845.1625.12N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.25N/AN/AN/A-47.79%-60.06%-17.37%11/24/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6538.4313.482.398.32%11.18%6.88%10/29/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest ARWR, RVMD, ALNY, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
8/4/2026Q3 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.23-$1.36-$0.13-$1.36$44.17 million$75.25 million
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.77
5.90
5.90
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
711140.86 million135.79 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
September 17 at 4:00 AM  |  fool.comhttps://www.fool.com/investing/2026/09/17/revolution-medicines-just-hit-a-major-milestone-is-the-stock-a-buy/
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
September 16 at 10:51 AM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/revolution-medicines-rvmd-promising-clinical-results-signal-potential-paradigm-shift-1838983/
Revolution Medicines (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 92,531 Shares
September 16 at 5:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-16/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $18,724,573.16 in Stock
September 15 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-insider-sells-1872457316-in-stock-2026-09-15/
Revolution Meds granted Breakthrough status for Rasonque
September 15 at 5:18 PM  |  thepharmaletter.comT
Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer
September 14 at 8:40 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-gets-us-fda-203523883.html
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
September 14 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361540/0/en/revolution-medicines-announces-u-s-fda-breakthrough-therapy-designation-for-rasonque-daraxonrasib-in-combination-with-chemotherapy-for-first-line-metastatic-pancreatic-cancer.html
National Pension Service Invests $51.24 Million in Revolution Medicines, Inc. $RVMD
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-national-pension-service-invests-5124-million-in-revolution-medicines-inc-rvmd-2026-09-13/
Revolution Medicines, Inc. $RVMD Shares Acquired by HighTower Advisors LLC
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-acquired-by-hightower-advisors-llc-2026-09-13/
A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.
MarketBeat Week in Review – 09/07 - 09/11 (RVMD)
...
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/marketbeat-week-in-review-09-07-09-11/
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
September 11, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/revolution-medicines-rvmd-gets-its-first-approved-drug-and-the-market-shrugs-1834240/
Lorence Kim Sells 17,090 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-11/
Revolution Medicines, Inc. $RVMD Position Trimmed by Tidal Investments LLC
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-position-trimmed-by-tidal-investments-llc-2026-09-11/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells 17,090 Shares of Stock
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-director-sells-17090-shares-of-stock-2026-09-10/
Revolution Medicines, Inc. $RVMD Shares Bought by Arizona State Retirement System
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-bought-by-arizona-state-retirement-system-2026-09-10/
California State Teachers Retirement System Has $44.66 Million Stock Holdings in Revolution Medicines, Inc. $RVMD
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-boosts-stock-holdings-in-revolution-medicines-inc-rvmd-2026-09-09/
Hsbc Holdings PLC Acquires 39,025 Shares of Revolution Medicines, Inc. $RVMD
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-acquires-39025-shares-of-revolution-medicines-inc-rvmd-2026-09-09/
Revolution Medicines, Inc. $RVMD Shares Purchased by Saudi Central Bank
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-purchased-by-saudi-central-bank-2026-09-08/
Readystate Asset Management LP Grows Position in Revolution Medicines, Inc. $RVMD
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-readystate-asset-management-lp-grows-position-in-revolution-medicines-inc-rvmd-2026-09-07/
Nykredit A S Purchases New Shares in Revolution Medicines, Inc. $RVMD
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-purchases-new-shares-in-revolution-medicines-inc-rvmd-2026-09-06/
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
September 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-stock-looks-141319320.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
By Chris Markoch | September 4, 2026
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$241.25 +1.89 (+0.79%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$68.39 +2.60 (+3.95%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$217.32 +1.31 (+0.60%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$197.53 +1.61 (+0.82%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas